Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Recursion Pharmaceuticals stock

Learn how to easily invest in Recursion Pharmaceuticals stock.

Recursion Pharmaceuticals is a biotechnology business based in the US. Recursion Pharmaceuticals shares (RXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Recursion Pharmaceuticals employs 550 staff and has a trailing 12-month revenue of around $50 million.

How to buy Recursion Pharmaceuticals stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – RXRX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 in stock when you fund a new account within 30 days

Promoted for social trading

Finder Award

eToro


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for active trading

tastytrade


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Recursion Pharmaceuticals stock price (NASDAQ: RXRX)

Use our graph to track the performance of RXRX stocks over time.

Recursion Pharmaceuticals shares at a glance

Information last updated 2023-09-17.
Latest market close$7.97
52-week range$4.54 - $16.75
50-day moving average $10.33
200-day moving average $8.40
Wall St. target price$15.71
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.41

Buy Recursion Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 7 of 7
Name Product Ratings Available asset types Minimum deposit Signup bonus
SoFi Invest
Finder Rating: 4.6 / 5: ★★★★★

Finder Award
SoFi Invest
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
Get up to $1,000 in stock
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
eToro
Finder Rating: 4.2 / 5: ★★★★★

Finder Award
EXCLUSIVE
eToro
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
tastytrade
Finder Rating: 4.1 / 5: ★★★★★
tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures
$0
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Public.com
Finder Rating: 4 / 5: ★★★★★
Public.com
★★★★★
Stocks, ETFs, Cryptocurrency, Art, Treasury Bills, Collectibles
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
2.5% fee applies to all alternative asset transactions.
Robinhood
Finder Rating: 4.2 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4.9% interest on uninvested cash in your account with Robinhood Gold.
JPMorgan Self-Directed Investing
Finder Rating: 4 / 5: ★★★★★
JPMorgan Self-Directed Investing
★★★★★
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
$0
Get $50 - $700
when you open and fund an account with $5,000 - $250,000+
Pay no commissions on stocks, ETFs, mutual funds and options.
Wealthfront
Finder Rating: 4 / 5: ★★★★★
Wealthfront
★★★★★
Stocks, ETFs
$500
N/A
Wealthfront builds a free financial plan for the life you want and automate your investments at a low cost.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Recursion Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Recursion Pharmaceuticals price performance over time

Historical closes compared with the close of $7.97 from 2023-09-21

1 week (2023-09-15) -7.00%
1 month (2023-08-22) -12.22%
3 months (2023-06-22) 3.37%
6 months (2023-03-22) 14.18%
1 year (2022-09-22) -25.58%
2 years (2021-09-22) -67.34%
3 years (2020-09-18) N/A
5 years (2018-09-18) N/A

Recursion Pharmaceuticals financials

Revenue TTM $50 million
Gross profit TTM $-164,128,000
Return on assets TTM -25.83%
Return on equity TTM -57.36%
Profit margin 0%
Book value $2.27
Market Capitalization $1.9 billion

TTM: trailing 12 months

Recursion Pharmaceuticals share dividends

We're not expecting Recursion Pharmaceuticals to pay a dividend over the next 12 months.

Recursion Pharmaceuticals share price volatility

Over the last 12 months, Recursion Pharmaceuticals's shares have ranged in value from as little as $4.54 up to $16.745. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Recursion Pharmaceuticals's is -0.1656. This would suggest that Recursion Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Recursion Pharmaceuticals has bucked the trend.

To put Recursion Pharmaceuticals's beta into context you can compare it against those of similar companies.

Recursion Pharmaceuticals overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc. ; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Recursion Pharmaceuticals is owned by insiders or institutions?
Currently 6.796% of Recursion Pharmaceuticals shares are held by insiders and 88.927% by institutions.
How many people work for Recursion Pharmaceuticals?
Latest data suggests 550 work at Recursion Pharmaceuticals.
When does the fiscal year end for Recursion Pharmaceuticals?
Recursion Pharmaceuticals's fiscal year ends in December.
Where is Recursion Pharmaceuticals based?
Recursion Pharmaceuticals's address is: 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101
What is Recursion Pharmaceuticals's ISIN number?
Recursion Pharmaceuticals's international securities identification number is: US75629V1044

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site